APR 1 9 2006 W

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Khan et al.

Serial No.: 10/821,240

Filed: April 8, 2004

For: METHODS AND USES FOR PROTEIN BREAKDOWN PRODUCTS

Confirmation No.: 9732

Examiner: To be assigned

Group Art Unit: 1648

Attorney Docket No.: 3077-6384US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL995984783US

Date of Deposit with USPS: April 12, 2006

Person making Deposit: Tim Palfreyman

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).



<u>U.S. Patent No.</u> US - 6,727,227 U.S. Patent Documents

Publication Date

04-27-2004

Patentee |

Serial No.: 10/821,240

Khavinson

Foreign Patent Documents

<u>Document No.</u> WO 01/29067 Publication Date 04-26-2001

Patentee Obschestvo S Ogra

Obschestvo S Ogranichennoi Otvetstvennostiju "Klinika Instituta Bioregulyatsii I Gerontologii"

Other Documents

IVANOV et al., "Hemoglobin as a Source of Endogenous Bioactive Peptides: The Concept of Tissue-Specific Peptide Pool," Biopolymers, 1997, pp. 171-188, Vol. 39.

KHAVINSON et al, Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland.

KHAVINSON et al., "Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People," Bulletin of Experimental Biology and Medicine, October 2002, pp. 389-392, Vol. 134, No. 4.

KHAVINSON et al., "Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects," Bulletin of Experimental Biology and Medicine, January 2004, pp. 78-81, Vol. 137, No. 1.

KHAVINSON et al., "Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells," Bulletin of Experimental Biology and Medicine, June 2003, pp. 590-592, Vol. 135, No. 6.

KHAVINSON et al., "Inductive Activity of Retinal Peptides," Bulletin of Experimental Biology and Medicine, November 2002, pp. 482-484, Vol. 134, No. 5.

KHAVINSON et al., "Mechanisms Underlying Geroprotective Effects of Peptides," Bulletin of Experimental Biology and Medicine, January 2002, pp. 1-5, Vol. 133, No. 1.

Serial No.: 10/821,240

KHAVINSON et al., "Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell," Bulletin of Experimental Biology and Medicine, May 2004, pp. 503-506, Vol. 137, No. 5.

MOROZOV et al., "Natural and Synthetic Thymic Peptides as Therapeutics for Immune Dysfunction," Int. J. Immunopharmac., 1997, pp. 501-505, Vol. 19, No. 9/10.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.:

2183-4799.1US

Serial No.:

11/037,972

Filed:

1/18/2005

Title:

IMMUNOREGULATOR

Attorney Docket No.:

3077-6418US

Serial No.:

11/243,438

Filed:

10/4/2005

Title:

COMPOSITIONS FOR MUCOSAL AND ORAL

ADMINISTRATION COMPRISING HCG FRAGMENTS

Attorney Docket No.:

3077-6420.2US

Serial No.:

11/249,541

Filed:

10/13/2005

Title:

COMPOSITIONS CAPABLE OF REDUCING ELEVATED BLOOD

UREA CONCENTRATION

Attorney Docket No.:

3077-7568US

Serial No.:

11/286,571

Filed:

11/23/2005

Title:

COMPOUNDS OF THERAPEUTIC VALUE IN THE TREATMENT

OF MULTIPLE SCLEROSIS AND OTHER DISEASES

WHEREIN FOAM CELLS ARE INVOLVED IN THE DISEASE

ETIOLOGY

Serial No.: 10/821,240

Attorney Docket No.:

3077-7643US

Serial No.:

11/346,450 2/2/2006

Filed: Title:

COMPOSITIONS CAPABLE OF REDUCING ELEVATED BLOOD

UREA CONCENTRATION

Attorney Docket No.:

3077-7568.1US

Serial No.:

11/346,761 2/3/2006

Filed: Title:

COMPOUNDS OF THERAPEUTIC VALUE IN THE TREATMENT

OF MULTIPLE SCLEROSIS AND OTHER DISEASES

WHEREIN FOAM CELLS ARE INVOLVED IN THE DISEASE

ETIOLOGY

This Supplemental Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits; therefore, no fee is due. If the Office determines that a fee is required, please charge TraskBritt Deposit Account No. 20-1469.

Respectfully submitted,

Allen C. Turner

Registration No. 33,041 Attorney for Applicants TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: April 12, 2006

ACT/alb

Enclosures: Form PTO/SB/08

Copy of documents cited

Document in ProLaw

PTO/SB/08A (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known 10/821,240 INFORMATION DISCLOSURE Application Number April 8, 2004 STATEMENT BY APPLICANT Filing Date First Named Inventor Khan et al. Group Art Unit 1648 (use as many sheets as necessary) Examiner Name To be assigned Sheet of 3077-6384US Attorney Docket Number

Examiner Initials *		Document Number		Name of Patentee or Applicant of	·
	Cite No.	Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-6,727,227	04-27-2004	Khavinson	
		US-			-
		US-			
		US-			*

Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ³ (<i>if known</i>)	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)		Applicant of Cited		T ⁶
		MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	
	WO 01/29067	04-26-2001	Obschestvo S Ogranichennoi Otvetstvennostiju "Klinika Instituta Bioregulyatsii I Gerontologii"		
		WO 01/29067	WO 01/29067 04-26-2001	"Klinika Instituta Bioregulyatsii I	"Klinika Instituta Bioregulyatsii I

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B(10-03)
Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 10/821,240 INFORMATION DISCLOSURE Filing Date April 8, 2004 STATEMENT BY APPLICANT First Named Inventor Khan et al. 1648 Group Art Unit (use as many sheets as necessary) Examiner Name To be assigned Attorney Docket Number 3077-6384US

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publicity and/or country where published.		
		IVANOV et al., "Hemoglobin as a Source of Endogenous Bioactive Peptides: The Concept of Tissue-Specific Peptide Pool," Biopolymers, 1997, pp. 171-188, Vol. 39.		
		KHAVINSON et al, Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland.		
		KHAVINSON et al., "Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People," Bulletin of Experimental Biology and Medicine, October 2002, pp. 389-392, Vol. 134, No. 4.		
		KHAVINSON et al., "Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects," Bulletin of Experimental Biology and Medicine, January 2004, pp. 78-81, Vol. 137, No. 1.		
		KHAVINSON et al., "Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells," Bulletin of Experimental Biology and Medicine, June 2003, pp. 590-592, Vol. 135, No. 6.		
		KHAVINSON et al., "Inductive Activity of Retinal Peptides," Bulletin of Experimental Biology and Medicine, November 2002, pp. 482-484, Vol. 134, No. 5.		
		KHAVINSON et al., "Mechanisms Underlying Geroprotective Effects of Peptides," Bulletin of Experimental Biology and Medicine, January 2002, pp. 1-5, Vol. 133, No. 1.		
		KHAVINSON et al., "Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell," Bulletin of Experimental Biology and Medicine, May 2004, pp. 503-506, Vol. 137, No. 5.		
		MOROZOV et al., "Natural and Synthetic Thymic Peptides as Therapeutics for Immune Dysfunction," Int. J. Immunopharmac., 1997, pp. 501-505, Vol. 19, No. 9/10.		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.